MENU
+Compare
ARQT
Stock ticker: NASDAQ
AS OF
Apr 3 closing price
Price
$16.16
Change
-$0.44 (-2.65%)
Capitalization
1.92B

ARQT Arcutis Biotherapeutics Forecast, Technical & Fundamental Analysis

Arcutis Biotherapeutics Inc is a medical dermatology company... Show more

ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ARQT with price predictions
Apr 03, 2025

Momentum Indicator for ARQT turns negative, indicating new downward trend

ARQT saw its Momentum Indicator move below the 0 level on April 03, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In of the 81 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ARQT moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on March 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARQT broke above its upper Bollinger Band on March 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where ARQT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

ARQT moved above its 50-day moving average on March 05, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on March 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 302 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 182 cases where ARQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.195) is normal, around the industry mean (13.581). P/E Ratio (0.000) is within average values for comparable stocks, (64.662). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.879). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (9.960) is also within normal values, averaging (248.206).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ARQT is expected to report earnings to rise 125.44% to -20 cents per share on May 20

Arcutis Biotherapeutics ARQT Stock Earnings Reports
Q1'25
Est.
$-0.20
Q4'24
Beat
by $0.19
Q3'24
Beat
by $0.09
Q2'24
Beat
by $0.09
Q1'24
Beat
by $0.37
The last earnings report on February 25 showed earnings per share of -9 cents, beating the estimate of -28 cents. With 2.76M shares outstanding, the current market capitalization sits at 1.92B.
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of treatments for dermatological diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
3027 Townsgate Road
Phone
+1 805 418-5006
Employees
296
Web
https://www.arcutis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSMAX84.65N/A
N/A
Fidelity Extended Market Index
RMDAX4.30N/A
N/A
Virtus Silvant Mid-Cap Growth A
NBHIX14.14N/A
N/A
Neuberger Berman Equity Income I
FWWFX32.51N/A
N/A
Fidelity Worldwide
HUSEX26.16N/A
N/A
Huber Small Cap Value Instl

ARQT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with KRYS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-2.47%
KRYS - ARQT
41%
Loosely correlated
-1.58%
IDYA - ARQT
39%
Loosely correlated
-4.77%
RYTM - ARQT
38%
Loosely correlated
-4.12%
XENE - ARQT
38%
Loosely correlated
-2.48%
BPMC - ARQT
37%
Loosely correlated
-3.22%
More